Request Demo
Last update 04 Aug 2026
Alpha-0261
Last update 04 Aug 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms AM 001, AM-001, AM001 + [1] |
Target |
Action modulators |
Mechanism MRGPRX2 modulators(MAS related GPR family member X2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with Alpha-0261NCT07744646
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Alpha-0261 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis (UC)
NCT07684560
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Oral Doses of Alpha-0261 Tablets in Patients With Chronic Spontaneous Urticaria, and the Effect of Food in Healthy Participants.
ChiCTR2600127494
An open-label, single-arm, multicenter study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of Alpha-0261 tablets in patients with moderate to severe active ulcerative colitis (UC)
100 Clinical Results associated with Alpha-0261
Login to view more data
100 Translational Medicine associated with Alpha-0261
Login to view more data
100 Patents (Medical) associated with Alpha-0261
Login to view more data
100 Deals associated with Alpha-0261
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colitis, Ulcerative | Phase 1 | China | 03 Aug 2026 | |
| Chronic Urticaria | Phase 1 | China | 01 Jul 2026 | |
| Moderate Atopic Dermatitis | Phase 1 | China | 06 Mar 2026 | |
| Severe Atopic Dermatitis | Phase 1 | China | 06 Mar 2026 | |
| Dermatitis, Atopic | Phase 1 | - | 21 Aug 2025 | |
| Urticaria | Preclinical | United States | 03 Jun 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free